ABSTRACT
Currently available therapies for chronic hepatitis B virus (HBV) infection can efficiently reduce viremia but induce hepatitis B surface antigen (HBsAg) loss in very few patients; also, these therapies do not greatly affect the viral covalently closed circular DNA (cccDNA). To discover new agents with complementary anti-HBV effects, we performed a drug repurposing screen of 1,018 Food and Drug Administration (FDA)-approved compounds using HBV-infected primary human hepatocytes (PHH). Several compounds belonging to the family of retinoic acid receptor (RAR) agonists were identified that reduced HBsAg levels in a dose-dependent manner without significant cytotoxicity. Among them, tazarotene exhibited the most potent anti-HBV effect, with a half-maximal inhibitory concentration (IC50) for HBsAg of less than 30 nM in PHH. The inhibitory effect was also observed in HBV-infected differentiated HepaRG (dHepaRG) models, but not in HepG2.215 cells, and HBV genotypes A to D were similarly inhibited. Tazarotene was further demonstrated to repress HBV cccDNA transcription, as determined by the levels of HBV cccDNA and RNAs and the activation of HBV promoters. Moreover, RNA sequence analysis showed that tazarotene did not induce an interferon response but altered the expression of a number of genes associated with RAR and metabolic pathways. Inhibition of RARß, but not RARα, by a specific antagonist significantly attenuated the anti-HBV activity of tazarotene, suggesting that tazarotene inhibits HBV in part through RARß. Finally, a synergistic effect of tazarotene and entecavir on HBV DNA levels was observed. Therefore, RAR agonists as represented by tazarotene were identified as potential novel anti-HBV agents.
Subject(s)
Antiviral Agents/pharmacology , Guanine/analogs & derivatives , Hepatitis B virus/drug effects , Host-Pathogen Interactions/drug effects , Nicotinic Acids/pharmacology , Receptors, Retinoic Acid/genetics , Acitretin/pharmacology , Adapalene/pharmacology , Cell Line , Cell Survival/drug effects , Dermatologic Agents/pharmacology , Drug Repositioning , Drug Synergism , Gene Expression , Guanine/pharmacology , Hep G2 Cells , Hepatitis B Surface Antigens/genetics , Hepatitis B Surface Antigens/metabolism , Hepatitis B e Antigens/genetics , Hepatitis B e Antigens/metabolism , Hepatitis B virus/genetics , Hepatitis B virus/growth & development , Hepatocytes/drug effects , Hepatocytes/metabolism , Hepatocytes/virology , High-Throughput Screening Assays , Host-Pathogen Interactions/genetics , Humans , Keratolytic Agents/pharmacology , Receptors, Retinoic Acid/agonists , Receptors, Retinoic Acid/metabolism , Transcription, Genetic/drug effects , Tretinoin/pharmacology , Virus Replication/drug effectsABSTRACT
Effects of energy supply and nicotinic acid (NA) supplementation on the phagocytic activity of polymorphonuclear leukocytes (PMN) and peripheral blood mononuclear cells (PBMC), and on ROS production in PMN of periparturient cows differing in parity were examined. 29 pluriparous and 18 primiparous cows were allocated to four different feeding groups from 42days prepartum until 100days postpartum. They were fed either a ration with a low concentrate proportion of 30% (LC) or a high concentrate proportion of 60% (HC). After parturition all animals received 30% concentrate which was increased to 50% either within 16 (LC) or within 24days (HC). The different concentrate feeding strategies aimed at triggering differences in postpartum lipolysis. Half of the animals per group were supplemented with 24g per day of NA from 42days prepartum until 24days postpartum. All investigated parameters varied significantly over time compared to parturition (p<0.05). Numbers of phagocytosing PMN and PBMC increased in the course of the experiment, whereas the amount of engulfed bacteria per cell decreased between 42 and 11days prepartum. Percentage of basal ROS producing PMN decreased strongly before parturition and reached initial values only at 28days in milk again. Mean fluorescence intensity (MFI) in these ROS producing cells, however, increased before parturition. Oxidative burst stimulation in PMN was reduced around parturition but the amount of ROS produced in the stimulated cells was increased. Pluriparous cows exhibited higher numbers of basal ROS producing PMN and phagocytic PBMC. NA supplementation influenced phagocytosis in blood leukocytes.
Subject(s)
Cattle/physiology , Leukocytes/drug effects , Nicotinic Acids/pharmacology , Parity , Phagocytosis/drug effects , Reactive Oxygen Species/metabolism , Animal Feed , Animal Nutritional Physiological Phenomena , Animals , Cattle/blood , Diet/veterinary , Dietary Supplements , Female , Lactation/physiology , Leukocytes/physiology , Peripartum Period/physiology , Phagocytosis/physiology , Pregnancy , Respiratory BurstABSTRACT
The interleukin-23/interleukin 17A (IL-23/IL-17A) cytokine axis plays a critical role in the pathogenesis of psoriasis. In this study, we report the effects of topical calcipotriol, camptothecin, clobetasol and tazarotene on the treatment of imiquimod (IMQ)-induced psoriasis-like inflammation, the development of which is dependent on the IL-23/IL-17A axis. IMQ-induced epidermal hyperplasia and inflammation in the BALB/c mouse ear were significantly inhibited following clobetasol treatment but not calcipotriol, camptothecin or tazarotene treatments. Real-time polymerase chain reaction showed that the mRNA levels of IL-17A, IL-17F, IL-22, IL-1ß, IL-6 and TNF-α in ear skin were significantly decreased by clobetasol. In addition, we observed that calcipotriol, camptothecin and tazarotene failed to show any inhibitory effects on the IL-23/IL-17A/IL-22 axis. We also found that clobetasol treatment inhibited the proliferation of γδ T cells and C-C chemokine receptor type 6 (CCR6) expression induced by IMQ. Calcipotriol, camptothecin and tazarotene not only failed to inhibit this proliferation but also enhanced retinoic acid-related orphan receptor γ (RORγ) expression in IMQ-induced psoriasis-like inflammation. In conclusion, we suggest that clobetasol induces the relief of IMQ-induced psoriasis-like inflammation in a mouse model but that calcipotriol, camptothecin and tazarotene cannot. Therefore, we suggest that more in-depth studies on pharmacological effects of tazarotene, camptothecin and calcipotriol should be carried out.
Subject(s)
Adjuvants, Immunologic/adverse effects , Aminoquinolines/adverse effects , Anti-Inflammatory Agents/pharmacology , Calcitriol/analogs & derivatives , Camptothecin/pharmacology , Clobetasol/pharmacology , Dermatologic Agents/pharmacology , Nicotinic Acids/pharmacology , Psoriasis , Topoisomerase I Inhibitors/pharmacology , Adjuvants, Immunologic/pharmacology , Administration, Topical , Aminoquinolines/pharmacology , Animals , Calcitriol/pharmacology , Disease Models, Animal , Humans , Imiquimod , Mice , Mice, Inbred BALB C , Psoriasis/chemically induced , Psoriasis/drug therapy , Psoriasis/pathologyABSTRACT
The orexin (or hypocretin) system has been identified as a novel target for the treatment of insomnia due to the wealth of biological and genetic data discovered over the past decade. Recently, clinical proof-of-concept was achieved for the treatment of primary insomnia using dual (OX1R/OX2R) orexin receptor antagonists. However, elucidation of the pharmacology associated with selective orexin-2 receptor antagonists (2-SORAs) has been hampered by the lack of orally bioavailable, highly selective small molecule probes. Herein, the discovery and optimization of a novel series of 2,5-diarylnicotinamides as potent and orally bioavailable orexin-2 receptor selective antagonists is described. A compound from this series demonstrated potent sleep promotion when dosed orally to EEG telemetrized rats.
Subject(s)
Nicotinic Acids/chemistry , Nicotinic Acids/pharmacology , Orexin Receptor Antagonists , Animals , Dogs , Drug Evaluation, Preclinical , Half-Life , Humans , Nicotinic Acids/chemical synthesis , Nicotinic Acids/pharmacokinetics , Orexin Receptors/metabolism , Protein Binding/drug effects , Rats , Structure-Activity RelationshipABSTRACT
The object of this study was to evaluate the potential of a recently developed preactivated thiolated pectin derivative as mucoadhesive excipient in drug delivery to the gastric cavity. Pectin (Pec) was chemically modified with L-cysteine (Cys). The free thiol groups of resulting thiomer were activated with 2-mercaptonicotinic acid (MNA) in order to improve stability and reactivity of attached thiol groups over a broad pH range. Multiunit dosage form properties of the resulting conjugate (Pec-Cys-MNA) were compared to unmodified pectin and the intermediate thiolated using rosuvastatin calcium as a model drug in loaded minitablets. Obtained results were compared with unmodified pectin and the intermediate thiolated pectin. Approximately half of attached thiol groups (507 µmol/g polymer) have been preactivated. Minitablets were evaluated regarding mucoadhesive properties, hardness, disintegration behavior, swelling characteristics and release of rosuvastatin calcium. Mediated by covalent bonds between the polymer and cysteine-rich subdomains in mucus, total work of adhesion increased more than 5-fold. The modification had no impact on hardness of compressed tablets but implementation of the aromatic ligand went along with reduction in hydrophilic properties. Disintegration time was prolonged more than 2-fold while water uptake capacity increased. Weight gain for Pec-Cys-MNA was at least 16-fold. Further, a sustained release of rosuvastatin calcium over 36 h was determined. Neither biodegradability nor CaCo-2 cell viability was affected. The study shows that Pec-Cys-MNA is a promising excipient for the development of mucoadhesive gastric dosage form.
Subject(s)
Cysteine/chemistry , Gastric Mucosa/drug effects , Gastrointestinal Agents/chemistry , Nicotinic Acids/chemistry , Pectins/chemistry , Sulfhydryl Compounds/chemistry , Animals , Caco-2 Cells , Cell Survival/drug effects , Cell Survival/physiology , Cysteine/pharmacology , Delayed-Action Preparations/chemistry , Delayed-Action Preparations/pharmacology , Drug Evaluation, Preclinical/methods , Gastric Mucosa/metabolism , Gastrointestinal Agents/pharmacology , Humans , Nicotinic Acids/pharmacology , Pectins/pharmacology , Sulfhydryl Compounds/pharmacology , Swine , TabletsABSTRACT
This study was conducted to determine the effects of dietary supplementation with Cr nicotinate and Cr chloride and their optimum inclusion rate on performance, carcass traits, meat oxidative stability, serum metabolites, hematological parameters, and liver chromium concentration in heat-stressed broilers. A total number of 420, 1-day-old male broiler chicks were randomly assigned to seven treatments with four replicates of 15 chicks. The dietary treatments consisted of the basal diet supplemented with 0 (control), 500, 1,000, and 1,500 µg/kg Cr in the form of Cr nicotinate and Cr chloride. Chicks were raised for 6 weeks in heat stress condition (33 ± 2°C). Supplements of organic and inorganic Cr particularly at 1,500 µg/kg incorporation increased feed consumption (P < 0.05) and body mass gain of broilers (P < 0.01). Cr supplementation increased carcass yield and decreased abdominal fat (P < 0.01). Supplementation of 1,500 µg/kg Cr nicotinate (P < 0.05) enhanced liver Cr concentration. Storage time increased lipid oxidation of meat (P < 0.01). Cr decreased lipid oxidation of breast and thigh muscles over 2 (P < 0.01) or 6 (P < 0.05) days of storage time. Birds fed 1,500 µg/kg Cr nicotinate, had lower concentration of serum glucose and triglyceride at 21 days (P < 0.05). Hematological parameters tested at 21 and 42 days, were not influenced. The results suggested that dietary Cr supplementation regardless of its source have a positive effect on productive, and carcass traits, also enhances oxidative stability of refrigerated meat in broilers reared under heat stress conditions.
Subject(s)
Body Weight/drug effects , Chlorides/pharmacology , Chromium Compounds/pharmacology , Meat/analysis , Nicotinic Acids/pharmacology , Organometallic Compounds/pharmacology , Animals , Animals, Newborn , Blood Cell Count , Blood Glucose/metabolism , Chickens , Chlorides/administration & dosage , Cholesterol/blood , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Chromium Compounds/administration & dosage , Dietary Supplements , Hematocrit , Hemoglobins/metabolism , Hot Temperature , Lipid Metabolism/drug effects , Male , Nicotinic Acids/administration & dosage , Organometallic Compounds/administration & dosage , Oxidation-Reduction/drug effects , Proteins/metabolism , Stress, Physiological/drug effects , Time Factors , Triglycerides/bloodABSTRACT
An in vitro screening protocol was used to transform a systemically-distributed SCD inhibitor into a liver-targeted compound. Incorporation of a key nicotinic acid moiety enables molecular recognition by OATP transporters, as demonstrated by uptake studies in transfected cell lines, and likely serves as a critical component of the observed liver-targeted tissue distribution profile. Preclinical anti-diabetic oGTT efficacy is demonstrated with nicotinic acid-based, liver-targeting SCD inhibitor 10, and studies with a close-structural analog devoid of SCD1 activity, suggest this efficacy is a result of on-target activity.
Subject(s)
Enzyme Inhibitors/chemistry , Hypoglycemic Agents/chemistry , Hypoglycemic Agents/pharmacology , Nicotinic Acids/chemistry , Stearoyl-CoA Desaturase/antagonists & inhibitors , Administration, Oral , Animals , Cell Line , Drug Evaluation, Preclinical , Enzyme Activation/drug effects , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacokinetics , Enzyme Inhibitors/pharmacology , Humans , Hypoglycemic Agents/chemical synthesis , Hypoglycemic Agents/pharmacokinetics , Liver/drug effects , Liver/enzymology , Mice , Mice, Inbred C57BL , Nicotinic Acids/chemical synthesis , Nicotinic Acids/pharmacokinetics , Nicotinic Acids/pharmacology , Rats , Stearoyl-CoA Desaturase/metabolism , Structure-Activity Relationship , Tissue DistributionABSTRACT
Sugar beet is highly sensitive to imidazolinone herbicides thus rotational restrictions exist. In order to develop imidazolinone tolerant sugar beets als gene from Arabidopsis thaliana encoding acetolactate synthase with S653N mutation was used for genetic transformation. Transgenic sugar beet plants were obtained by Agrobacterium-mediated transformation of aseptic seedlings using vacuum-infiltration. The efficiency of genetic transformation was 5.8%. RT-PCR analysis of obtained plants revealed accumulation of specific als transcript. The resistance to imidazolinone was proved for developed transgenic sugar beet plants in vitro and in greenhouse conditions after spraying with imazethapyr (Pursuit, BASF).
Subject(s)
Beta vulgaris/drug effects , Herbicides/pharmacology , Imidazolines/pharmacology , Nicotinic Acids/pharmacology , Plants, Genetically Modified/drug effects , Rhizobium/genetics , Transformation, Genetic , Arabidopsis/genetics , Beta vulgaris/genetics , Beta vulgaris/growth & development , Herbicide Resistance , Herbicides/chemistry , Imidazolines/chemistry , Nicotinic Acids/chemistry , Plants, Genetically Modified/growth & development , Polymerase Chain Reaction , Seeds/drug effects , Seeds/genetics , Seeds/growth & developmentABSTRACT
BACKGROUND: Spinal cord glutamate transporters clear synaptically released glutamate and maintain normal sensory transmission. However, their ultrastructural localization is unknown. Moreover, whether and how they participate in inflammatory pain has not been carefully studied. METHODS: Immunogold labeling with electron microscopy was carried out to characterize synaptic and nonsynaptic localization of glutamate transporters in the superficial dorsal horn. Their expression and uptake activity after formalin- and complete Freund's adjuvant (CFA)-induced inflammation were evaluated by Western blot analysis and glutamate uptake assay. Effects of intrathecal glutamate transporter activator (R)-(-)-5-methyl-1-nicotinoyl-2-pyrazoline and inhibitors (DL-threo-ß-benzyloxyaspartate [TBOA], dihydrokainate, and DL-threo-ß-hydroxyaspartate), or TBOA plus group III metabotropic glutamate receptor antagonist (RS)-α-methylserine-O-phosphate, on formalin- and CFA-induced inflammatory pain were examined. RESULTS: In the superficial dorsal horn, excitatory amino acid carrier 1 is localized in presynaptic membrane, postsynaptic membrane, and axonal and dendritic membranes at nonsynaptic sites, whereas glutamate transporter-1 and glutamate/aspartate transporter are prominent in glial membranes. Although expression of these three spinal glutamate transporters was not altered 1 h after formalin injection or 6 h after CFA injection, glutamate uptake activity was decreased at these time points. Intrathecal (R)-(-)-5-methyl-1-nicotinoyl-2-pyrazoline had no effect on formalin-induced pain behaviors. In contrast, intrathecal TBOA, dihydrokainate, and DL-threo-ß-hydroxyaspartate reduced formalin-evoked pain behaviors in the second phase. Intrathecal TBOA also attenuated CFA-induced thermal hyperalgesia at 6 h after CFA injection. The antinociceptive effects of TBOA were blocked by coadministration of (RS)-α-methylserine-O-phosphate. CONCLUSION: Our findings suggest that spinal glutamate transporter inhibition relieves inflammatory pain through activation of inhibitory presynaptic group III metabotropic glutamate receptors.
Subject(s)
Amino Acid Transport System X-AG/metabolism , Inflammation/metabolism , Pain/metabolism , Animals , Aspartic Acid/pharmacology , Blotting, Western , Disease Models, Animal , Formaldehyde , Freund's Adjuvant , Glutamic Acid/metabolism , Kainic Acid/analogs & derivatives , Kainic Acid/pharmacology , Male , Nicotinic Acids/pharmacology , Phosphoserine/pharmacology , Posterior Horn Cells/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Metabotropic Glutamate/metabolism , Spinal Cord/cytologyABSTRACT
Altered cellular mitochondrial membrane potential (MMP) has been implicated in the increased insulin resistance and the risk for diabetes. Hyperketonemia is increasingly being identified in type 2 diabetic patients in addition to those with type 1 diabetes. No previous study has examined the effect of hyperketonemia and trivalent chromium on cellular mitochondrial membrane potential (MMP) in any cell type. Using a U937 monocyte cell culture model, this study examined the hypothesis that hyperketonemia decreases and trivalent chromium normalizes the cellular MMP level. Cells were cultured with control and ketone bodies [acetoacetate (AA), ß-hydroxybutyrate (BHB)] in the absence or the presence (0.5-100 µM) of Cr(3+) at 37°C for 24 h. The MMP was determined using DiOC6 and flow cytometry. The results show a significant decrease in MMP in cells treated with AA, but not in the cells treated with BHB. The effect of AA on cellular MMP was prevented in chromium (III)-pretreated cells. Thus, hyperketonemia decreases the MMP, and supplementation with chromium (III) normalizes altered MMP, which may play a role in the improvement in glucose metabolism seen after chromium (III) supplementation in some studies with diabetic animals and patients.
Subject(s)
3-Hydroxybutyric Acid/pharmacology , Acetoacetates/pharmacology , Ketosis/physiopathology , Membrane Potential, Mitochondrial/drug effects , Monocytes/drug effects , Nicotinic Acids/pharmacology , Organometallic Compounds/pharmacology , Cell Survival/drug effects , Dietary Supplements , Humans , Monocytes/physiology , U937 CellsABSTRACT
Although curcumin displays several beneficial properties, its medicinal use is limited by its low bioavailability. In the present study we report the antioxidant potentials of two bioconjugates of curcumin with nicotinic acid and picolinic acid: di-O-nicotinoyl curcumin [1,7-bis (4-O nicotinoyl-3-methoxyphenyl)-1,6-heptadiene-3, 5-dione] and di-O-picolinoyl curcumin [1,7-bis (4-O-picolinoyl-3-methoxyphenyl)-1,6-heptadiene-3, 5-dione], in terms of ferric reducing, radical scavenging and beta-carotene bleaching abilities, and comparing the observed activity with that of curcumin. Results demonstrate that both the bioconjugates possess higher antioxidant potentials as evidenced by enhanced ferric reducing, radical scavenging and beta-carotene bleaching abilities, in comparison with curcumin. On the basis of our results we conclude that these bioconjugates of curcumin may be better than curcumin for medicinal and pharmacological applications.
Subject(s)
Antioxidants/pharmacology , Curcumin/analogs & derivatives , Free Radical Scavengers/pharmacology , Nicotinic Acids/pharmacology , Picolinic Acids/pharmacology , beta Carotene/chemistry , Curcumin/pharmacology , Ferric Compounds/chemistry , Oxidation-ReductionABSTRACT
The pharmacokinetics of N-(5-oxynicotinoyl)-L-glutamate (ONG) was studied in rats (doses, 20, 100 and 500 mg/kg) and rabbits (50 mg/kg) after bolus administration of calcium salt of N-(5-oxynicotinoyl)-L-glutamic acid (Ampasse preparation). The ONG concentration in the blood serum was determined by HPLC assay with fluorimetric detection. The lower limit of accurate detection for ONG was 100 ng/ml. The ONG pharmacokinetics in rats was linear at relatively small doses (20-100 mg/kg) but nonlinear at a large dose (500 mg/kg). The ONG concentration decay had a two-phase character in both rats and rabbits, so that the pharmacokinetic profiles were fitted to a biexponential equation of the two-compartment model. Systemic pharmacokinetic parameters determined in rats and rabbits, respectively, were as follows: total clearance, 18 and 15 ml/(min kg); steady state distribution volume, 330 and 880 ml/kg; mean retention time, 0.3 and 1.0 h; half-life, 0.73 and 2.3 h. Using the allometric approach to the interspecies extrapolation of the pharmacokinetic data, the half-life of ONG in humans is predicted to be 4 h.
Subject(s)
Glutamates/pharmacokinetics , Neuroprotective Agents/pharmacokinetics , Nicotinic Acids/pharmacokinetics , Nootropic Agents/pharmacokinetics , Animals , Glutamates/pharmacology , Male , Neuroprotective Agents/pharmacology , Nicotinic Acids/pharmacology , Nootropic Agents/pharmacology , Rabbits , Rats , Rats, Wistar , Species SpecificityABSTRACT
1,6-Dimethyl-4-hydroxy-3-pyridinecarboxylic acid (DQ716) and 4-hydroxy-2-methyl-3-pyridinecarboxylic acid (DQ2) were evaluated for possible application to iron (Fe) and aluminium (Al) chelation therapy. Metal/ligand solution chemistry, electrochemistry, cytotoxicity, octanol/water partitioning (D(o/w)), and chelation efficiency, were studied. The Fe(iii)/DQ716, Fe(iii)/DQ2, Al(iii)/DQ716, and Al(iii)/DQ2 solution chemistry was investigated in aqueous 0.6 mol kg(-1) (Na)Cl at 25 degrees C by means of potentiometric titrations, UV-vis spectrophotometry, and (1)H-NMR spectroscopy. DQ716 exhibited the highest coordination efficiency towards Fe(iii) and Al(iii) among all hydroxypyridinecarboxylic acids examined so far, whereas DQ2 complexes were significantly less stable. These results were confirmed by chelation efficiency measurements performed in an octanol-aqueous solution in the presence of those ligands and metals. Partitioning experiments at pH 7.4 showed both DQ716 and DQ2, and their Fe(iii) and Al(iii) complexes, to be hydrophilic. According to the voltammetric data, the free ligands (DQ716 and DQ2) and their metal complexes are not predicted to undergo redox cycling at in vivo conditions. The standard reduction potentials of these complexes, and the kinetics of their formation and dissociation, were obtained. The toxicity of DQ716 and of DQ2 was investigated with human cancer cell lines and normal human fibroblasts. Cytotoxic effects were observed only for DQ2 at 0.1 mM, following 3 d exposure. According to our results, DQ716 has the required favourable properties to be a chelating agent for Fe and Al.
Subject(s)
Aluminum/chemistry , Chelating Agents/chemistry , Iron/chemistry , Nicotinic Acids/chemistry , Cell Line, Tumor , Cell Survival/drug effects , Chelating Agents/pharmacology , Crystallography, X-Ray , Electrochemistry , HeLa Cells , Humans , Magnetic Resonance Spectroscopy , Nicotinic Acids/pharmacology , ThermodynamicsABSTRACT
This study tested the hypothesis that 3-acetyl-7-oxo-dehydroepiandrosterone alone (7-Keto) and in combination with calcium citrate, green tea extract, ascorbic acid, chromium nicotinate and cholecalciferol (HUM5007) will increase the resting metabolic rate (RMR) of overweight subjects maintained on a calorie-restricted diet. In this randomized, double-blind, placebo-controlled, crossover trial, overweight adults on a calorie-restricted diet were randomized to three 7-day treatment periods with 7-Keto, HUM5007 or placebo. Resting metabolic rate was measured by indirect calorimetry at the beginning and end of each treatment period with a 7-day washout between testing periods. Of 45 subjects enrolled, 40 completed the study (30 women, 10 men; mean age, 38.5 years; mean mass index, 32.0 kg/m(2)). During the placebo treatment, RMR decreased by 3.9% (75+/-111 kcal/day; mean+/-S.D.); however, RMR increased significantly by 1.4% (21+/-115 kcal/day) and 3.4% (59+/-118 kcal/day) during the 7-Keto and HUM5007 treatment periods, respectively (each compared to placebo, P=.001). No significant differences were found between the treatment periods with respect to compliance or adverse events. In this study, the administration of HUM5007 or 7-Keto reversed the decrease in RMR normally associated with dieting. HUM5007 and 7-Keto increased RMR above basal levels and may benefit obese individuals with impaired energy expenditure. HUM5007 and 7-Keto were generally well tolerated and no serious adverse events were reported.
Subject(s)
Ascorbic Acid/pharmacology , Basal Metabolism/drug effects , Cholecalciferol/pharmacology , Dehydroepiandrosterone/analogs & derivatives , Nicotinic Acids/pharmacology , Plant Extracts/pharmacology , Adult , Ascorbic Acid/administration & dosage , Caloric Restriction , Camellia sinensis , Cholecalciferol/administration & dosage , Dehydroepiandrosterone/administration & dosage , Dehydroepiandrosterone/pharmacology , Double-Blind Method , Drug Combinations , Female , Humans , Male , Middle Aged , Nicotinic Acids/administration & dosage , Organometallic Compounds/administration & dosage , Organometallic Compounds/pharmacology , Overweight , Plant Extracts/administration & dosageABSTRACT
Topical and oral retinoids have been successfully used in antipsoriatic therapy over the last 50 years. Development of more selective agents has led to an improved efficacy and safety profile. The first topical receptor-selective retinoid to be approved for the treatment of plaque psoriasis is tazarotene. Topical tazarotene displays an onset of action and efficacy similar to those of other established antipsoriatic agents. Common adverse events of this agent such as pruritus, burning, local skin irritation, and erythema are limited to the skin and generally mild or moderate in severity. Although effective as monotherapy, evidence is accumulating that combining topical tazarotene with other established antipsoriatic therapies results in enhanced efficacy and reduced adverse events. In particular, concomitant use of topical tazarotene with a mid-potency or high-potency corticosteroid in the treatment of psoriatic plaques enhances efficacy and reduces the risk of corticosteroid-induced skin atrophy. Combination of phototherapy with tazarotene accelerates the clinical response and diminishes the cumulative UVB or psoralen plus UVA (PUVA) exposure load. Recently, an oral form of tazarotene has been developed. The results of completed phase III clinical trials of this agent indicate a beneficial effect in moderate to severe plaque psoriasis. Adverse events are generally of mild severity, and most of those observed, such as cheilitis and dry skin, are typical of hypervitaminosis A. Of note, oral tazarotene appears not to be associated with other adverse events that are typical of oral retinoids, including hypertriglyceridemia and hypercholesterolemia. However, since head-to-head trials with acitretin (the only retinoid currently approved for systemic therapy) have not been conducted, it is unclear whether tazarotene is any safer or more effective than acitretin. Moreover, the major drawback of oral tazarotene is teratogenicity, which may limit its use in female patients. Further studies evaluating long-term clinical outcomes with oral tazarotene and its use in combination therapies are awaited.
Subject(s)
Dermatologic Agents/pharmacology , Nicotinic Acids/pharmacology , Psoriasis/drug therapy , Retinoids/pharmacology , Animals , Clinical Trials as Topic , Female , Humans , Male , Receptors, Retinoic Acid/drug effectsABSTRACT
BACKGROUND & OBJECTIVE: The occupational and non-occupational exposure to hexavalent chromium Cr (VI) is common. The effect of chromium compromises the immune response of the host. Dengue virus (DV) infection causes various changes in the peripheral blood cells. It is, therefore, possible that the chromium toxicity may affect the disease process during DV infection. The present study aims to study the effects of dengue virus infection on peripheral blood cells of mice fed Cr (VI) with drinking water. METHODS: One group of mice was given ad libitum drinking water containing Cr (VI) and the other group used as the normal control mice was given plain water to drink. At the 3, 6 and 9 wk of Cr (VI) drinking, a set of mice from each group was inoculated intracerebrally (ic) with DV and studied at the 4th and 8th day post inoculation. RESULTS: It was observed that Cr (VI) drinking led to reduction in lymphocytes, haemoglobin and the haematocrit values while the granulocyte, monocyte and platelet counts were increased. On the other hand, most of the parameters were decreased following inoculation of normal mice with DV. In Cr (VI)-fed mice the effects of DV infection were minimal. The most significant finding of these experiments was that the reduction in platelet counts following inoculation with DV was markedly less in Cr (VI)-fed mice than that in DV-inoculated normal control mice. INTERPRETATION & CONCLUSION: Cr(VI) compounds have been declared as a potent occupational carcinogen. On the contrary, Cr(III) salts such as chromium polynicotinate, chromium chloride and chromium picolinate, are used as micronutrients and nutritional supplements, and have been shown to exhibit health benefits in animals and humans. Whether therapeutic doses of chromium (III) compounds may be able to prevent the DV-induced fall in platelet counts, needs to be investigated.
Subject(s)
Chromium/therapeutic use , Dengue Virus/metabolism , Dengue/drug therapy , Dengue/pathology , Administration, Oral , Animals , Blood Cell Count , Blood Platelets/cytology , Carcinogens , Chlorides/pharmacology , Chromium/administration & dosage , Chromium/pharmacology , Chromium Compounds/pharmacology , Erythrocytes/drug effects , Erythrocytes/virology , Hematocrit , Humans , Leukocytes/drug effects , Leukocytes/virology , Lymphocytes/drug effects , Lymphocytes/virology , Mice , Monocytes/drug effects , Monocytes/virology , Neutrophils/drug effects , Neutrophils/virology , Nicotinic Acids/pharmacology , Organometallic Compounds/pharmacology , Picolinic Acids/pharmacology , Platelet Count , Time Factors , Water/metabolismABSTRACT
Tazarotene (Tazorac) is a topical retinoid indicated for the treatment of plaque psoriasis. When used as monotherapy, topical tazarotene was effective at controlling signs and symptoms of plaque psoriasis, and had significantly lower post-treatment relapse rates than fluocinonide cream. The most common adverse events associated with tazarotene therapy are skin-associated events, such as pruritus, burning, and erythema. Combination therapy with tazarotene and mid-to-high potency topical corticosteroids generally resulted in a greater therapeutic effect than that with tazarotene alone, reduced the irritancy of tazarotene, and decreased the risk of post-treatment disease flare seen with corticosteroids; it also has the potential to reduce the degree of skin atrophy associated with topical corticosteroids. The combination of tazarotene and phototherapy also appears promising. Thus, tazarotene, as monotherapy or in combination with topical corticosteroids or UV light therapy, represents a useful treatment option in patients with plaque psoriasis.
Subject(s)
Keratolytic Agents/therapeutic use , Nicotinic Acids/therapeutic use , Psoriasis/therapy , Retinoids/therapeutic use , Administration, Topical , Adrenal Cortex Hormones/therapeutic use , Combined Modality Therapy , Humans , Keratolytic Agents/pharmacology , Nicotinic Acids/pharmacology , Retinoids/pharmacology , Ultraviolet TherapyABSTRACT
Atherosclerosis is a complex vascular disease initiated by abnormal accumulation of plasma lipoproteins in the subendothelial space. Elevated levels of plasma triglycerides (TG) and low-density lipoprotein (LDL)-cholesterol as well as low concentrations of high-density lipoprotein (HDL) play a causal role in the development and progression of atherosclerotic lesions. We have shown that apolipoprotein E-deficient (apo E-KO) mice have elevated triglyceride levels plus diminished HDL concentrations. Drugs such as fenofibrate and nicotinic acid are well known to reduce TG and increase HDL levels in humans. In this study, we investigated the beneficial effects of fenofibrate and niacin on lipid profile and atherogenesis in apo E-KO mice and their wild-type counterparts. Animals were fed with a cholesterol-enriched diet supplemented with fenofibrate (0.1% wt/wt, n = 8) or nicotinic acid (0.5% wt/wt, n = 8) for 14 weeks. Body weights were recorded weekly, and plasma lipid profiles were determined at 4-week intervals. The hearts and aortas were collected and fixed for histologic and morphometric evaluations of atherosclerotic lesions. Fenofibrate treatment in apo E-KO mice paradoxically increased total cholesterol and TG by 65% and 44%, respectively, and decreased HDL-cholesterol levels by 35% as compared with controls. Similar effects of fenofibrate on cholesterol levels, but not on TG concentrations, were observed in C57BL/6 mice. Fenofibrate-treated mice had lower body weight as compared with controls. Niacin had no effect on body weight gain but failed to decrease TG or to increase HDL levels in either apo E-KO mice or their wild-type counterparts. Neither fenofibrate nor niacin significantly influenced atherogenesis in apo E-KO mice as compared with controls. In conclusion, this study shows that neither niacin nor fenofibrate has beneficial lipid-modifying and antiatherosclerosis activities in mice. Identification of mechanisms underlying paradoxical effects of fenofibrate on lipoprotein metabolisms in apo E-KO mice merits further investigation.
Subject(s)
Apolipoproteins E/deficiency , Fenofibrate/pharmacology , Nicotinic Acids/pharmacology , Animals , Aorta/drug effects , Aorta/pathology , Apolipoproteins E/genetics , Arteriosclerosis/blood , Arteriosclerosis/etiology , Arteriosclerosis/prevention & control , Body Weight/drug effects , Cholesterol, Dietary/administration & dosage , Cholesterol, HDL/blood , Fenofibrate/administration & dosage , Humans , Hypolipidemic Agents/administration & dosage , Hypolipidemic Agents/pharmacology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Nicotinic Acids/administration & dosage , Triglycerides/blood , Vitamin B Complex/administration & dosage , Vitamin B Complex/pharmacologyABSTRACT
We investigated the influence of blood perfusion on local heating of the forearm and middle finger skin following 42.25 GHz exposure with an open ended waveguide (WG) and with a YAV mm wave therapeutic device. Both sources had bell-shaped distributions of the incident power density (IPD) with peak intensities of 208 and 55 mW/cm(2), respectively. Blood perfusion was changed in two ways: by blood flow occlusion and by externally applied vasodilator (nonivamide/nicoboxil) cream to the skin. For thermal modeling, we used the bioheat transfer equation (BHTE) and the hybrid bioheat equation (HBHE) which combines the BHTE and the scalar effective thermal conductivity equation (ETCE). Under normal conditions with the 208 mW/cm(2) exposure, the cutaneous temperature elevation (DeltaT) in the finger (2.5 +/- 0.3 degrees C) having higher blood flow was notably smaller than the cutaneous DeltaT in the forearm (4.7 +/- 0.4 degrees C). However, heating of the forearm and finger skin with blood flow occluded was the same, indicating that the thermal conductivity of tissue in the absence of blood flow at both locations was also the same. The BHTE accurately predicted local hyperthermia in the forearm only at low blood flow. The HBHE made accurate predictions at both low and high perfusion rates. The relationship between blood flow and the effective thermal conductivity (k(eff)) was found to be linear. The heat dissipating effect of higher perfusion was mostly due to an apparent increase in k(eff). It was shown that mm wave exposure could result in steady state heating of tissue layers located much deeper than the penetration depth (0.56 mm). The surface DeltaT and heat penetration into tissue increased with enlarging the irradiating beam area and with increasing exposure duration. Thus, mm waves at sufficient intensities could thermally affect thermo-sensitive structures located in the skin and underlying tissue.
Subject(s)
Electromagnetic Fields , Fingers/physiology , Forearm/physiology , Hyperthermia, Induced/methods , Skin Temperature/physiology , Skin/blood supply , Capsaicin/analogs & derivatives , Capsaicin/pharmacology , Energy Transfer , Fingers/radiation effects , Forearm/radiation effects , Forecasting , Humans , Models, Biological , Nicotinic Acids/pharmacology , Regional Blood Flow/drug effects , Regional Blood Flow/physiology , Regional Blood Flow/radiation effects , Skin/drug effects , Skin/radiation effects , Skin Temperature/drug effects , Skin Temperature/radiation effects , Thermal Conductivity , Vasodilator Agents/pharmacologyABSTRACT
Multiple seeded cocklebur has been found in the last decade in Texas, and described as a biotype of Xanthium strumarium L with up to 25 seeds per bur instead of the usual two. The multiple seeded bur typically produces up to nine seedlings, causing concern that it may be harder to control than normal seeded common cocklebur. The efficacies of a series of fungal and conventional commercial herbicides have been compared in the greenhouse on seedlings of multiple seeded cocklebur from Texas (MSC-TX) and normal common cockleburs from Texas (NCC-TX), Arkansas (NCC-AR), Illinois (NCC-ILL) and two from Mississippi (NCC-MS#1, NCC-MS#2). Three measures of herbicidal activity (reductions in plant height and dry weight, and mortality) were used. The fungal herbicide Alternaria helianthi (Hansf) Tubaki & Nishihara at 1 x 10(5) conidia ml(-1) + 2 g liter(-1) Silwet L-77 with an 8-h dew period was an effective herbicide with all biotypes, as were the commercial chemical herbicides chlorimuron (14.8 g ha(-1)), imazaquin (29.6 g ha(-1)), sodium hydrogen methylarsonate (MSMA; 279.1 g ha(-1)) and imazethapyr (39.5 g ha(-1)). The membrane-disrupting organic arsenical MSMA was effective with all biotypes, whereas commercial chemical herbicides which act by inhibiting branched-chain amino acid synthesis (chlorimuron, imazaquin and imazethapyr) were less effective against normal seeded common cocklebur biotypes with short stature. These studies showed that multiple seeded cocklebur was at least as susceptible to the biological agent A helianthi and to the conventional commercial herbicides studied as were normal seeded cockleburs, suggesting that existing methods should be adequate to control this novel biotype.